Quick Answer
BioNexus Gene Lab Corp reported Shares Outstanding of 17.97 million shares for fiscal year 2024.
BioNexus Gene Lab Corp Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2024 | 17.97M | +1.7% |
| 2023 | 17.67M | +22.0% |
| 2022 | 14.48M | -91.5% |
| 2021 | 171.22M | +0.0% |
| 2020 | 171.22M | +66.7% |
| 2019 | 102.73M | +37.7% |
| 2018 | 74.63M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 1.80M | -90.0% | +0.0% |
| June 30, 2025 | 1.80M | -89.8% | -90.0% |
| March 31, 2025 | 17.97M | +1.7% | +900.0% |
| December 31, 2024 | 1.80M | -89.8% | -90.0% |
| September 30, 2024 | 17.97M | — | +1.7% |
| June 30, 2024 | 17.67M | -89.8% | +0.0% |
| March 31, 2024 | 17.67M | -89.8% | +0.0% |
| December 31, 2023 | 17.67M | -89.8% | -89.8% |
- BioNexus Gene Lab Corp showed an increase of +1.7% in Shares Outstanding compared to the prior fiscal year.
- Over the 2018–2024 period, BioNexus Gene Lab Corp’s shares outstanding has declined by 75.9% (from 74.63 million shares to 17.97 million shares).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: